NCT00387725View on ClinicalTrials.gov

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Healthy
Interventions
BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

Trial Locations (9)

2031

Sydney Children's Hospital, Randwick

2145

The Children's Hospital at Westmead, Westmead

4006

Royal Children's Hospital, Herston

6008

Princess Margaret Hospital for Children, Subiaco

QLD 4006

Sir Albert Sakzewski Virus Research Centre (SASVRC), Herston

SA 5006

Women's & Children's Hospital, North Adelaide

WA 6008

The Telethon Institute for Child Health Research, Subiaco

NSW 2145

National Centre for Immunisation, Westmead

ACT 2606

Department of Paediatrics and Child Health, Woden

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY